Related Experiment Video
Updated: Oct 17, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis
1Department of Internal Medicine, Cancer Research Center, Seoul National University College of Medicine, Korea.
Abstract:
An inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, lovastatin, induces growth arrest and cell death in a wide variety of malignant cells in vitro. We analyzed the effect of lovastatin on myeloid leukemic cell lines. Lovastatin significantly inhibited the proliferation of 7 cell lines among 11 myeloid leukemic cell lines in a dose-dependent manner. In order to address the mechanism of antileukemic effect of lovastatin, cell cycle analysis was attempted in HL-60 cells, showing that lovastatin induced G1 arrest in HL-60 cells following 72 h of drug exposure (1.5 microM, 5 microM and 10 microM) in a dose-dependent manner. Analysis of G1 regulatory proteins demonstrated that the protein levels of cyclin-dependent kinase (CDK) 2, CDK4, CDK6 and cyclin E were decreased after treatment with lovastatin (10 microM) in a time-dependent manner, but not cyclin D1. In addition, lovastatin increased the protein level of the cyclin-dependent kinase inhibitor (CDKI), p27, and markedly enhanced the binding of p27 with CDK2 and CDK4 more than CDK6 after 24 h exposure. At higher doses of lovastatin (50 mM, 100 mM, 200 mM), a significant apoptosis was observed as evidenced by FACS analysis with annexin V staining, which was associated with downregulation of Bcl-2 protein. These results suggest that lovastatin inhibits the proliferation of myeloid leukemic cells via G1 arrest in association with p27 induction and is an effective inducer of apoptosis in HL-60 cells.
Insights
Lovastatin, an HMG-CoA reductase inhibitor, effectively halts myeloid leukemic cell proliferation by inducing G1 cell cycle arrest and apoptosis. This mechanism involves p27 induction and Bcl-2 downregulation, highlighting lovastatin
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, demonstrates in vitro anti-cancer properties against various malignant cells.
- Myeloid leukemias are a group of cancers affecting myeloid cells, necessitating research into novel therapeutic agents.
Purpose of the Study:
- To investigate the anti-leukemic effects of lovastatin on myeloid leukemic cell lines.
- To elucidate the underlying mechanisms of lovastatin's anti-leukemic activity, focusing on cell cycle regulation and apoptosis.
Main Methods:
- Proliferation assays were performed on 11 myeloid leukemic cell lines treated with lovastatin.
- Cell cycle analysis (G1 arrest) and Western blot analysis of G1 regulatory proteins (CDKs, cyclins, CDKI p27) were conducted on HL-60 cells.
- Apoptosis was assessed using fluorescence-activated cell sorting (FACS) with annexin V staining and Bcl-2 protein levels were analyzed.
Main Results:
- Lovastatin significantly inhibited proliferation in 7 out of 11 myeloid leukemic cell lines in a dose-dependent manner.
- Lovastatin induced G1 cell cycle arrest in HL-60 cells, correlating with decreased levels of CDK2, CDK4, CDK6, and cyclin E, and increased p27 levels.
- Higher doses of lovastatin induced significant apoptosis, associated with Bcl-2 downregulation.
Conclusions:
- Lovastatin exhibits anti-proliferative effects on myeloid leukemic cells, primarily through G1 cell cycle arrest mediated by p27 induction.
- Lovastatin effectively induces apoptosis in HL-60 cells, suggesting its potential as a therapeutic agent for myeloid leukemias.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
02:34Inhibition of Cdk Activity